Gene therapy of primary T cell immunodeficiencies.

Abstract : Gene therapy of severe combined immunodeficiencies has been proven to be effective to provide sustained correction of the T cell immunodeficiencies. This has been achieved for 2 forms of SCID, i.e SCID-X1 (γc deficiency) and adenosine deaminase deficiency. Occurrence of gene toxicity generated by integration of first generation retroviral vectors, as observed in the SCID-X1 trials has led to replace these vectors by self inactivated (SIN) retro(or lenti) viruses that may provide equivalent efficacy with a better safety profile. Results of ongoing clinical studies in SCID as well as in other primary immunodeficiencies, such as the Wiskott Aldrich syndrome, will be thus very informative.
Type de document :
Article dans une revue
Gene, Elsevier, 2013, 525 (2), pp.170-173. 〈10.1016/j.gene.2013.03.092〉
Liste complète des métadonnées

Littérature citée [37 références]  Voir  Masquer  Télécharger
Contributeur : Alain Fischer <>
Soumis le : jeudi 25 avril 2013 - 12:32:17
Dernière modification le : jeudi 22 mars 2018 - 15:56:02
Document(s) archivé(s) le : vendredi 26 juillet 2013 - 04:03:15


Fichiers produits par l'(les) auteur(s)




Alain Fischer, Salima Hacein-Bey-Abina, Marina Cavazzana-Calvo. Gene therapy of primary T cell immunodeficiencies.. Gene, Elsevier, 2013, 525 (2), pp.170-173. 〈10.1016/j.gene.2013.03.092〉. 〈inserm-00817790〉



Consultations de la notice


Téléchargements de fichiers